Thanks for sharing. Seems like this is the natural progression of the technology and is a very positive step in the R&D journey. Anyone well versed with the science, please do let us know what is the adoption of dPCR at the moment and ow likely is it to increase quickly?
4 Likes
After CRISPER, here is a new technology that may have a disruptive effect on 3BBDx in future: Combination of optofluidics and nanopores technologies.
https://www.pnas.org/doi/10.1073/pnas.2400203121
https://news.ucsc.edu/2024/04/schmidt-pnas.html
2 Likes
Good results in my opinion – growth on all fronts
https://www.bseindia.com/xml-data/corpfiling/AttachLive/bd6e776e-db48-41c6-9d17-bd83ba983325.pdf
Couple of interesting highlights from the investor presentation:
Disc.: invested
15 Likes
Almost 10 % of the profit after tax was eaten by Rs. 1.39 Crore deferred tax expense booked in revenue account and added to deferred tax liabilities in the balance sheet. Such sum is not seen in previous years. I understand this as a sum which will become a positive factor in the coming years in the revenue account as a result of accounting adjustments of depreciation in the tax account and INDAS. Some accounting vizards in the community please explain…
6 Likes
4 Likes
7 Likes
3 Likes
There is likely to be a big addressable market for AMR in India.
3B will benefit in the next few years as they expand their sales presence.
6 Likes